Development of ovarian cancer-specific gene therapy by liposome-processed oncolytic adenovirus
| Project/Area Number |
26462527
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 産婦人科学 / オンコリティックアデノウイルス / リポソーム / 婦人科腫瘍 / コンドロイチン硫酸 / 抗体 / ヘパリン / アデノウイルス / 卵巣癌 |
|---|
| Outline of Final Research Achievements |
Negatively charged adenovirus was processed with positively charged liposomal DOPE/DOTAP/EPC formulated at a concentration of 8 mM at a ratio of 40%, 55%, 5% and further processed with negatively charged chondroitin sulfate having tumor specificity. Processed adenovirus showed tumor-specific anti-tumor effect even in the presence of anti-adenovirus antibody. Since weak negatively charged chondroitin sulfate was not able to sufficiently neutralize strongly positively charged liposomes, treatment with heparin having a strong negative charge shows a stronger antitumor effect even in the presence of the antibody as compared with adenovirus/liposome/chondroitin sulfate complex.
|
Report
(4 results)
Research Products
(14 results)
-
[Journal Article] A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity2016
Author(s)
Nosaki, K., Hamada, K., Takashima, Y., Sagara, M., Matsumura, Y., Miyamoto, S., Hijikata, Y., Okazaki, T., Nakanishi, Y., Tani, K.
-
Journal Title
Molecular Therapy-Oncolytics
Volume: 3
Pages: 1-9
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Biosafety studies of carrier cells infected with a replication-competent adenovirus introduced by IAI.3B promoter.2014
Author(s)
2.Hamada, K., Shirakawa, T., Terao, S., Gotoh, A., Tani, K., Huang, W.
-
Journal Title
Molecular Therapy--Methods & Clinical Development
Volume: 1
Pages: 1-11
DOI
Related Report
Peer Reviewed / Open Access
-
[Presentation] Development of new oncolytic virotherapies for malignancies.2016
Author(s)
Miyamoto, K., Nozaki,K., Sagara,M., Takishima,Y., Wang,B., Yang,J., Matsuura,K., Yotsuya,R.,Inoue,H., Yamada,K., Kohara,H., Ogata H., Hamada,K. Tani, K.
Organizer
第22回日本遺伝子細胞治療学会
Place of Presentation
東京都港区（虎ノ門ヒルズフォーラム）
Year and Date
2016-07-28
Related Report
-
[Presentation] Novel polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity.2016
Author(s)
Nosaki, K., Takishima, Y., Sagara, M.,Matsumura, Y.M., Miyamoto. S., Yang, J., Matsuura, K., Okazaki, T., lnoue, H., Nakanishi, Y., Hamada,K., Tani, K.
Organizer
第22回日本遺伝子細胞治療学会
Place of Presentation
東京都港区（虎ノ門ヒルズフォーラム）
Year and Date
2016-07-28
Related Report
-
-
-
-
[Presentation] Novel Polymer-Coated Stealth Oncolytic Measles Virus Overcame Immune Suppression and Induced Stronger Antitumor Activity.2015
Author(s)
Kaname Nosaki, Katsuyuki Hamada, Yuto Takishima, Miyako Sagara, Yumiko Matsumura, Shohei Miyamoto, Michiyo Okada, Yasuki Hijikata, Toshihiko Okazaki, Kazunari Yamada, Hiroyuki Inoue, Yoichi Nakanishi, Kenzaburo Tani.
Organizer
18th Annual Meeting of ASGCT
Place of Presentation
New Orleans
Year and Date
2015-05-13
Related Report
-
-
-
-
-
-
